Katsunori Shinozaki

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 282 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada et al. · Journal of Clinical Oncology · 2020 · 197 citations

Medicine, Oncology, Pharmacotherapy +16

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer

Nobuyuki Katakami, Toshiyuki Harada, Tōru Murata et al. · Journal of Clinical Oncology · 2017 · 139 citations

Medicine, Pharmacology, Pharmacotherapy +17

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

Kohei Shitara, Takeharu Yamanaka, Tadamichi Denda et al. · Annals of Oncology · 2018 · 87 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer

Nobuyuki Katakami, Koji Oda, Katsunori Tauchi et al. · Journal of Clinical Oncology · 2017 · 64 citations

Nursing, Pharmacology, Pharmacotherapy +17